Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Axsome Therapeutics (NASDAQ:AXSM) Chief Executive Officer Herriot Tabuteau sold a total of 62,880 shares of common stock between September 12 and September 16, 2025, for approximately $7.3 million. The sale comes as the stock, currently trading at $114.1, has experienced a 9.21% decline over the past week, though InvestingPro analysis suggests the company remains slightly undervalued based on its Fair Value model. The sales, executed under a pre-approved 10b5-1 plan, involved multiple transactions with prices ranging from $114.19 to $118.96 per share.
The transactions followed the exercise of stock options for a total of 62,880 shares at a price of $8.02, amounting to $504297.
Following these transactions, Tabuteau directly owns 7,229 shares of Axsome Therapeutics. Tabuteau also indirectly owns 7,344,500 shares in the $5.72 billion market cap company. Access the complete Axsome Therapeutics Pro Research Report, along with detailed financial metrics and expert analysis, through an InvestingPro subscription.
In other recent news, Axsome Therapeutics has been in the spotlight due to several key developments. The company received a Paragraph IV Certification Notice Letter from Apotex Inc., indicating that Apotex is seeking approval to produce a generic version of Axsome’s Symbravo medication. This has prompted reactions from analysts, with H.C. Wainwright reiterating a Buy rating and a $180.00 price target, and Mizuho maintaining an Outperform rating with a $200.00 price target. Additionally, Cantor Fitzgerald has maintained its Overweight rating and a $153.00 price target, although it slightly reduced its revenue projections for Axsome’s Sunosi medication. Wells Fargo has also initiated coverage with an Overweight rating and a $163.00 price target as Axsome prepares to submit a supplemental New Drug Application for its AXS-05 treatment. These developments are crucial for investors to consider as they assess Axsome’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.